Trial Profile
Using GM-CSF as a Host Directed Therapeutic Against COVID-19 - a Phase 2 Investigator Initiated Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Sargramostim (Primary)
- Indications Acute hypoxia; COVID 2019 infections; Respiratory insufficiency
- Focus Therapeutic Use
- 08 May 2022 Status changed from recruiting to completed.
- 04 Aug 2020 According to a Partner Therapeutics media release,funding will also support regulatory filings for a potential EUA and expansion of production capacity to meet increased demand.
- 04 Aug 2020 According to a Partner Therapeutics media release, the company announced a contract the U.S. Department of Defense (DOD) to fund two studies(NCT04411680 and NCT04400929) of Leukine in patients with COVID-19 patients associated acute hypoxemia.